Shanghai Bao Pharmaceuticals (HKG:2659) submitted filing materials related to the proposed implementation of its Hong Kong-listed share full circulation with the China Securities Regulatory Commission, according to a Tuesday Hong Kong bourse filing.
The biotechnology company is looking to convert over 63.1 million unlisted shares into Hong Kong-listed shares.
The shares represent around 19.36% of the firm's issued share capital.